Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of “Buy” from Analysts

Immuneering Corporation (NASDAQ:IMRX) has earned an average rating of “Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $17.50.

Several research firms recently issued reports on IMRX. Chardan Capital upgraded shares of Immuneering to a “strong-buy” rating in a report on Monday, August 3rd. Needham & Company LLC lifted their price objective on Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. UBS Group set a $14.00 price objective on Immuneering in a research note on Thursday, August 6th. HC Wainwright initiated coverage on Immuneering in a research report on Thursday, August 6th. They set a “buy” rating and a $14.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Immuneering in a research note on Wednesday, July 8th. They set an “overweight” rating and a $17.00 target price for the company.

Hedge Funds Weigh In On Immuneering

A number of institutional investors and hedge funds have recently modified their holdings of the business. Focus Financial Network Inc. acquired a new stake in Immuneering in the second quarter worth $62,000. PVG Asset Management Corp bought a new stake in shares of Immuneering in the 1st quarter worth $773,000. Weiss Asset Management LP purchased a new stake in Immuneering in the 1st quarter valued at about $464,000. Cetera Investment Advisers bought a new position in shares of Immuneering in the first quarter valued at approximately $67,000. Finally, Levin Capital Strategies L.P. purchased a new stake in shares of Immuneering during the 1st quarter valued at $53,000. 67.65% of the stock is currently owned by institutional investors.

Immuneering Stock Performance

NASDAQ:IMRX opened at $5.18 on Thursday. The company has a market capitalization of $335.13 million, a PE ratio of -4.98 and a beta of 0.43. The company has a 50 day simple moving average of $4.75 and a two-hundred day simple moving average of $4.99. Immuneering has a fifty-two week low of $3.86 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). Research analysts predict that Immuneering will post -1.07 EPS for the current year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.